News about "Antibody-Drug Conjugate "

PMDA Expands Use of Enhertu for Second-Line Gastric Cancer in Japan

Regulatory update allows Enhertu to be used earlier in treatment for HER2-positive advanced gastric cancer, backed by phase III data showing improved survival outcomes.

Antibody-drug Conjugate | 25/03/2026 | By News Bureau |  140

GSK plc Secures Japan Orphan Drug Status for Ris-Rez in Small-Cell Lung Cancer

Japan’s health ministry grants orphan drug designation to GSK’s investigational ADC Ris-Rez for SCLC, supported by early clinical data showing durable responses in advanced-stage patients.

Antibody-Drug Conjugate | 24/03/2026 | By News Bureau

Daiichi Sankyo Submits sNDA in Japan for Datroway in First-Line Metastatic TNBC

Daiichi Sankyo files supplemental application in Japan for Datroway as a first-line treatment for metastatic triple negative breast cancer based on phase III trial data.

Antibody Drug Conjugate | 13/02/2026 | By News Bureau |  137

First Patient Dosed in Phase III Tropian-Lung17 Trial of Datroway in Advanced NSCLC

The global Phase III study evaluates Datroway versus docetaxel in Trop2 NMR-positive advanced nonsquamous NSCLC patients previously treated with immunotherapy and platinum chemotherapy.

Antibody-Drug Conjugate | 14/01/2026 | By News Bureau |  148

MediLink, Roche Sign Global Licensing Deal for YL201 ADC Therapy

Agreement includes USD 570 million upfront and milestones to advance B7H3-targeting solid tumor cancer treatment worldwide.

Antibody-Drug Conjugate | 09/01/2026 | By News Bureau |  398

Harbour BioMed Signs Strategic Collaboration with Lannacheng on Radionuclide Drug Conjugates

Harbour BioMed has entered into a long-term strategic collaboration with Yantai Lannacheng Biotechnology to jointly advance the development of next-generation radionuclide drug conjugates, combining both companies’ resources and expertise to accelerate innovation in targeted radiopharmaceutical therapies.

Antibody Drug Conjugate | 30/12/2025 | By News Bureau

Enhertu Secures US BTD Status in Early HER2-Positive Breast Cancer

The US FDA has granted Breakthrough Therapy Designation to Enhertu for use as post-neoadjuvant treatment in patients with HER2-positive early breast cancer, marking the tenth such designation for AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate, supported by phase III DESTINY-Breast05 trial results.

Antibody Drug Conjugate | 23/12/2025 | By News Bureau |  115

GSK Gains Exclusive Rights to Syndivia's Prostate Cancer ADC

GSK has obtained exclusive rights from Syndivia for a preclinical Antibody-Drug Conjugate (ADC) targeting metastatic Castration-Resistant Prostate Cancer (mCRPC), addressing an urgent need for novel therapies. The agreement expands GSK’s oncology pipeline with a potential best-in-class ADC designed to deliver enhanced anti-tumour activity.

Antibody Drug Conjugate | 27/10/2025 | By Dineshwori |  291

CDSCO approves AstraZeneca's Trastuzumab Deruxtecan for More HER2-Positive Tumours

With this, Trastuzumab Deruxtecan becomes India’s first Antibody Drug Conjugate (ADC) approved for a tumour-agnostic indication.

Antibody Drug Conjugate | 04/10/2025 | By Dineshwori |  274

US FDA Grants Priority Review for Enhertu + Pertuzumab in HER2+ Metastatic Breast Cancer

The US FDA has granted Priority Review to Enhertu + Pertuzumab for HER2+ metastatic breast cancer, following DESTINY-Breast09 trial results showing a 44 percent reduction in risk of disease progression or death and over three years’ median Progression-Free Survival (PFS), positioning it as a potential new first-line standard of care.

Antibody Drug Conjugate | 25/09/2025 | By Dineshwori |  130